Alzheimer Disease Clinical Trial
Official title:
An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate Efficacy & Safety of MNI-558 Positron Emission Tomography for Detection/Exclusion of Cerebral Amyloid Beta in Patients w/ Alzheimer Disease Compared to Healthy Volunteers
This research will look at how the brain may change in people with Alzheimer disease (AD).
The purpose of this research is to find out whether changes in the brain in people with
Alzheimer disease can be detected using a brain imaging test. Most people with Alzheimer
disease have changes in the brain that result in deposits of a protein called beta-amyloid.
In this study, the investigators will be using a radioactive drug, [18F]MNI-558 that binds
to beta-amyloid. This drug is experimental and has not been approved by the FDA. Brain
imaging using PET (positron emission tomography) will be done to see if the investigators
can evaluate the areas of beta-amyloid in the subjects with Alzheimer disease. The
investigators will compare these scans with those done in healthy normal volunteers. PET is
a brain-scanning test used in medicine and scientific research to see how the brain is
working. The PET imaging test used in this study is not being done for diagnostic purposes.
This is a phase 0, open-label, single-center, non-randomized single dose study to assess the
safety and efficacy of MNI-558 PET imaging in detecting amyloid beta plaque in the brain in
patients with probable AD compared to HVs. All aspects related to image acquisition,
processing and visual as well as quantitative evaluation will be developed, optimized and
validated (where required).
Each subject will be required to visit the study center during the screening phase, on the
MNI-558 PET imaging day (baseline), and for 1 follow-up visit on the next day. A telephone
follow-up visit will be performed 7 days after MNI-558 PET administration.
At the screening visit, each subject and the caregiver will be asked to provide written
informed consent or assent. During the screening phase (maximum duration - 28 days) subject
medical, neurological and surgical history, clinical assessments and a neuro-psychiatric
evaluation will be performed on all eligible subjects. Subjects will be allowed to leave the
center after all evaluations have been completed. During this period an MRI of the brain
must be performed. During the MNI-558 PET imaging day, all subjects will receive a single IV
injection of IMP and scanning will be performed from 0-60 min, 75-135 min, and 150-210 min
(p.i). Each subject will be asked to return to the site for a follow-up visit (20 to 28
hours after IMP administration) and a telephone follow-up will occur 7 days thereafter.
Safety will be assessed during both follow-up visits.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |